Olema Pharmaceuticals Inc (OLMA)

Ollie’s reports mixed Q4 results; 2026 outlook tops expectationsMarch 12, 2026 10:34 AM
IH Market News
Ollie’s Bargain Outlet (NASDAQ:OLMA) reported fourth-quarter results that largely matched profit expectations while revenue came in slightly below forecasts, and the retailer issued a full-year outlook that exceeded market estimates.Adjusted earnings per share totaled $1.39 for the quarter, compared with analyst expectations of $1.41. Revenue increased 17% year-over-year to $779.25 million, falling short of the consensus estimate of $783.71 million.Comparable store sales rose 3.6% during the quarter, up from 2.8% in the same period last year. The company said the increase was driven by larger basket sizes and higher transaction volumes. Seasonal merchandise, consumables, hardware, stationery and sporting goods were among the top-performing categories.“We had a strong fourth quarter to cap off an exceptional year,” said Eric van der Valk, President and CEO. “In the fourth quarter, we delivered better than expected sales and earnings, driven by solid comp growth, healthy margins, and disciplined expense control. For the full year, we opened a record 86 stores and grew our Ollie’s Army loyalty program by more than 12% to 17 million members.”Adjusted EBITDA for the quarter reached $127.13 million, while gross margin was reported at 39.9%.Looking ahead, the company released its initial guidance for fiscal 2026, which ends January 30, 2027.Ollie’s expects adjusted earnings per share between $4.40 and $4.50 for the year, above analyst consensus of $3.91. Net sales are projected to range from $2.99 billion to $3.01 billion, also exceeding the $2.65 billion forecast by analysts.The retailer also anticipates comparable store sales growth of about 2% and a gross margin of approximately 40.5% for the year.Ollies Bargain Outlet Holdings stock price

Original: Ollie’s reports mixed Q4 results; 2026 outlook tops expectations

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMAMarch 9, 2026 1:57 PM
Business Wire
The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (“Olema” or “the Company”) (NASDAQ: OLMA) for violations of the securities laws.


INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Olema is the subject of an Investor’s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema’s competing medication. According to analyst Matthew Biegler, the Roche results "comes with a dent to the thesis that oral SERDs can win in front-line breast cancer." Based on this news, shares of Olema fell by more than 19.6% in morning trading on the same day.


If you are a shareholder who suffered a loss, contact us to participate.


WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.


This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309730374/en/
David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com


Original: Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

Olema Pharmaceuticals shares plunge 41% after Roche breast cancer trial setbackMarch 9, 2026 11:31 AM
IH Market News
Olema Pharmaceuticals (NASDAQ:OLMA) shares dropped 41% on Monday after negative results from a late-stage breast cancer study conducted by Roche weighed on sentiment across the sector.Roche reported that its Phase 3 persevERA trial evaluating giredestrant in combination with palbociclib versus an aromatase inhibitor plus palbociclib failed to meet its primary endpoint. The study did not achieve a statistically significant improvement in progression-free survival. Roche shares fell as much as 7.5% following the announcement, marking their biggest decline in more than 11 months.Olema is currently developing its own breast cancer treatment candidate, palazestrant, which is being tested in multiple Phase 3 trials. The company’s OPERA-02 study, evaluating palazestrant in first-line metastatic breast cancer, is not expected to deliver topline data until 2028.Although Roche reported a numerical improvement in outcomes during the trial, the results did not reach statistical significance.Stifel analysts said the development could weigh on Olema in the near term but noted that the trial still showed signs of potential benefit. They added that the data leave open the possibility that palazestrant’s stronger receptor antagonism and pharmacokinetic profile could offer a meaningful clinical advantage in first-line metastatic breast cancer treatment.The firm also noted that investors who believe palazestrant could achieve best-in-class status may view the current sell-off as an opportunity, as Roche’s setback could leave room for Olema’s therapy to emerge as an early leader in the first-line metastatic setting.Olema Pharmaceuticals stock price

Original: Olema Pharmaceuticals shares plunge 41% after Roche breast cancer trial setback

Olema plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Olema.
In connection with the proposed offering, Olema

$$22 + 159% great way to start morming next will look to short it ..

$20s cash out ...All out $$$$$$!!!$$$$&!$!$$$!🇧🇷🚀🚀🔥

$15.06 + 80%

$14.75 + 75%

$14 + 60% 

$13.17 + 50% $$$$$$

)12.37 +50% flip 10% on morming pump keep offloading slowly until $20 

$11.76 +38% cooking premarket Pfizer rocks 

$11.01 Pfizer association $20 by next year and good cancer stuff 

&9.30 Looking good 👍 ... Overview * Olema reports Q3 net loss of $42.2 mln due to increased R&D expenses * Company ends Q3 with $329 mln in cash and marketable securities * Announced clinical trial agreement with Pfizer for palazestrant and atirmociclib Outlook * Company to initiate Phase 1b/2 study with Pfizer in Q4 2025 * Olema to present trial poster at SABCS in December 2025 Result Drivers * CLINICAL TRIAL AGREEMENT - Announced agreement with Pfizer to evaluate palazestrant with atirmociclib in ER+/HER2- metastatic breast cancer Key Details Metric Beat/Mis Actual Consensu s s Estimate Q3 Net -$42.22 Income mln Q3 -$45.88 Income mln From Operatio ns Q3 $45.88 Operatin mln g Expenses Analyst Coverage * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" * The average consensus recommendation for the biotechnology & medical research peer group is "buy" * Wall Street's median 12-month price target for https://client.schwab.com/app/research/#/symbol/OLMA is $22.00, about 62% above its November 7 closing price of $8.35 Press Release:For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Nice Pfizer agreement been pushing nicely since Sep2 news a slow ride to $20 ..$8.05 + 20%

OLMA under $15

OLMA over $10

OLMA over $10

OLMA new 52 week high